{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:10:46Z","timestamp":1763536246482},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","geriatriconcology.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jgo.2024.101777","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T10:17:37Z","timestamp":1714817857000},"page":"101777","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient-reported outcomes and experiences from a prospective cohort study of older patients with cancer on checkpoint inhibitors: The ELDERS study"],"prefix":"10.1016","volume":"15","author":[{"given":"Fabio","family":"Gomes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binish","family":"Khatoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Punnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Farrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janelle","family":"Yorke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jgo.2024.101777_bb0005","first-page":"1668","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.jgo.2024.101777_bb0010","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jgo.2024.101777_bb0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.394","article-title":"Immune-related adverse events from immune checkpoint inhibitors","volume":"100","author":"Marrone","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jgo.2024.101777_bb0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: emerging concepts in aging of the immune system","volume":"19","author":"Nikolich-Zugich","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jgo.2024.101777_bb0025","author":"Cancer Research UK"},{"key":"10.1016\/j.jgo.2024.101777_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/107327480701400103","article-title":"Interaction between comorbidity and cancer","volume":"14","author":"Extermann","year":"2007","journal-title":"Cancer Control"},{"key":"10.1016\/j.jgo.2024.101777_bb0035","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/cncr.23315","article-title":"Dying with cancer: the influence of age, comorbidity, and cancer site","volume":"112","author":"Kendal","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2024.101777_bb0045","first-page":"2036","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.jgo.2024.101777_bb0050","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/annonc\/mdw259","article-title":"Inclusion of elderly patients in oncology clinical trials","volume":"27","author":"Le Saux","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2024.101777_bb0055","first-page":"400","article-title":"Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research","volume":"38","author":"Kanesvaran","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.jgo.2024.101777_bb0060","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40266-018-0573-z","article-title":"The role of targeted agents and immunotherapy in older patients with non-small cell lung cancer","volume":"35","author":"Gomes","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jgo.2024.101777_bb0065","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1002\/cam4.2940","article-title":"Cancer patients\u2019 experiences with immune checkpoint modulators: a qualitative study","volume":"9","author":"Ala-Leppilampi","year":"2020","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.jgo.2024.101777_bb0070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.12968\/bjcn.2011.16.3.146","article-title":"Patient-reported outcome measures: an overview","volume":"16","author":"Meadows","year":"2011","journal-title":"Br J Community Nurs"},{"issue":"4","key":"10.1016\/j.jgo.2024.101777_bb0080","first-page":"41","article-title":"Cancer, comorbidities, and health-related quality of life of older adults","volume":"29","author":"Smith","year":"2008","journal-title":"Health Care Financ Rev"},{"key":"10.1016\/j.jgo.2024.101777_bb0085","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00520-012-1688-0","article-title":"A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment","volume":"6","author":"Reilly","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jgo.2024.101777_bb0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1472-6963-13-211","article-title":"A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jgo.2024.101777_bb0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jamda.2013.01.009","article-title":"Priorities of health care outcomes for the elderly","volume":"14","author":"Akishita","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jgo.2024.101777_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.breast.2016.02.015","article-title":"Importance of patient reported outcome measures versus clinical outcomes for breast cancer patients evaluation on quality of care","volume":"27","author":"Kool","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.jgo.2024.101777_bb0105","doi-asserted-by":"crossref","unstructured":"Scott\u00e9 F, Bossi P, Carola E, Cudennec T, Dielenseger P, Gomes F, Knox S, Strasser F. Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide. Ann Oncol 2018; 29(8):1718\u20131726. https:\/\/doi\/org\/https:\/\/doi.org\/10.1093\/annonc\/mdy228.","DOI":"10.1093\/annonc\/mdy228"},{"issue":"11","key":"10.1016\/j.jgo.2024.101777_bb0110","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2024.101777_bb0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cllc.2018.05.011","article-title":"Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non\u2013small-cell lung cancer","volume":"19","author":"Bordoni","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"17","key":"10.1016\/j.jgo.2024.101777_bb0120","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2024.101777_bb0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2017.07.038","article-title":"Outcomes in patients with aggressive or refractory disease from REVEL: a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer","volume":"112","author":"Reck","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jgo.2024.101777_bb0130","first-page":"6(1)","article-title":"A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients \u2013 the ELDERS study","volume":"2021","author":"Gomes","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.jgo.2024.101777_bb0135","series-title":"Research Design: Qualitative, Quantitative, and Mixed Methods Approaches","first-page":"9","article-title":"A framework for design","author":"Creswell","year":"2003"},{"key":"10.1016\/j.jgo.2024.101777_bb0140","series-title":"The Foundations of Social Research: Meaning and Perspective in The Research Process","author":"Crotty","year":"2020"},{"key":"10.1016\/j.jgo.2024.101777_bb0145","doi-asserted-by":"crossref","unstructured":"Aaronson NK, Ahmedzai S, Bergman B Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365\u2013376. doi:https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","DOI":"10.1093\/jnci\/85.5.365"},{"issue":"2","key":"10.1016\/j.jgo.2024.101777_bb0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"10.1016\/j.jgo.2024.101777_bb0155","series-title":"NVivo 12 Essentials","author":"Edhlund","year":"2019"},{"key":"10.1016\/j.jgo.2024.101777_bb0160","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/bmj.322.7294.1115","article-title":"Checklists for improving rigour in qualitative research: a case of the tail wagging the dog?","volume":"322","author":"Barbour","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jgo.2024.101777_bb0165","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/1475-6773.12117","article-title":"Achieving integration in mixed methods designs-principles and practices","volume":"48","author":"Fetters","year":"2013","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jgo.2024.101777_bb0170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/pon.566","article-title":"Lay constructions of decision-making in cancer","volume":"11","author":"Henman","year":"2002","journal-title":"Psycho-Oncol"},{"key":"10.1016\/j.jgo.2024.101777_bb0175","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s00432-020-03336-1","article-title":"Patient expectations are better for immunotherapy than traditional chemotherapy for cancer","volume":"146","author":"Ihrig","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jgo.2024.101777_bb0180","doi-asserted-by":"crossref","unstructured":"Milne D, Hyatt A, Billett A, Gough K, Krishnasamy M. Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: \"real-world\" data. Cancer Nurs 2020;43(2): e97-e104. https:\/\/doi\/org\/https:\/\/doi.org\/10.1097\/NCC.0000000000000683.","DOI":"10.1097\/NCC.0000000000000683"},{"issue":"7059","key":"10.1016\/j.jgo.2024.101777_bb0185","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/bmj.313.7059.724","article-title":"Information needs of cancer patients in West Scotland: cross sectional survey of patients\u2019 views","volume":"313","author":"Meredith","year":"1996","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.jgo.2024.101777_bb0190","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa1204410","article-title":"Patients\u2019 expectations about effects of chemotherapy for advanced cancer","volume":"367","author":"Weeks","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jgo.2024.101777_bb0195","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jpainsymman.2013.10.016","article-title":"Perceptions of health status and survival in patients with metastatic lung cancer","volume":"48","author":"Greer","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"10.1016\/j.jgo.2024.101777_bb0200","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/pon.673","article-title":"Lay understanding of terms used in cancer consultations","volume":"12","author":"Chapman","year":"2003","journal-title":"Psycho-Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2024.101777_bb0205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pec.2016.08.006","article-title":"Communication during radiation therapy education sessions: the role of medical jargon and emotional support in clarifying patient confusion","volume":"100","author":"Schnitzler","year":"2017","journal-title":"Patient Educ Couns"},{"issue":"11","key":"10.1016\/j.jgo.2024.101777_bb0210","doi-asserted-by":"crossref","first-page":"e1190","DOI":"10.1634\/theoncologist.2018-0820","article-title":"Balancing the hype with reality: what do patients with advanced melanoma consider when making the decision to have immunotherapy?","volume":"24","author":"Wong","year":"2019","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2024.101777_bb0215","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/pon.656","article-title":"The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment","volume":"12","author":"Devine","year":"2003","journal-title":"Psycho-Oncol"},{"key":"10.1016\/j.jgo.2024.101777_bb0220","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s13187-020-01941-9","article-title":"The supportive care needs of cancer patients: a systematic review","volume":"36","author":"Evans Webb","year":"2021","journal-title":"J Cancer Educ"},{"issue":"6","key":"10.1016\/j.jgo.2024.101777_bb0225","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jgo.2019.12.015","article-title":"eHealth literacy in older adults with cancer","volume":"11","author":"Hoogland","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2024.101777_bb0230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13063-016-1391-4","article-title":"Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the quintet recruitment intervention (QRI)","volume":"17","author":"Donovan","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.jgo.2024.101777_bb0235","author":"Macmillan Cancer Support"},{"issue":"2","key":"10.1016\/j.jgo.2024.101777_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824000754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824000754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T21:12:40Z","timestamp":1717535560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406824000754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1879406824000754"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2024.101777","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes and experiences from a prospective cohort study of older patients with cancer on checkpoint inhibitors: The ELDERS study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2024.101777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101777"}}